

# FITCH, EVEN, TABIN & FLANNERY

ATTORNEYS AND COUNSELLORS AT LAW

*Established in 1859*

SUITE 401L - 1801 K STREET, NW  
WASHINGTON, D.C. 20006-1201

TELEPHONE (202) 419-7000

FACSIMILE (202) 419-7007

ILLINOIS OFFICE

SUITE 1600 - 120 SOUTH LA SALLE STREET, CHICAGO, ILLINOIS 60603-3406

TELEPHONE (312) 577-7000

CALIFORNIA OFFICE

SUITE 250 - 9276 SCRANTON ROAD, SAN DIEGO, CA 92121-7707

TELEPHONE (858) 552-1311

COLORADO OFFICE

SUITE 213 - 1942 BROADWAY, BOULDER, COLORADO 80302

TELEPHONE (303) 402-6966

MORGAN L. FITCH, JR.  
FRANCIS A. EVEN\*  
JULIUS TABIN  
JOHN F. FLANNERY  
ROBERT B. JONES  
JAMES J. SCHUMANN  
JAMES J. HAMILL  
TIMOTHY E. LEVSTIK  
JOSEPH E. SHIPLEY  
KENNETH H. SAMPLES  
PHILIP T. PETTI  
JOSEPH T. NABOR  
STEVEN C. SCHROER  
RICHARD A. KABA\*  
KARL R. FINK  
MARK W. HETZLER  
TIMOTHY P. MALONEY  
JAMES P. KRUEGER  
STEPHEN S. FAVAKEH  
EDWARD W. GRAY, JR.\*  
RICHARD E. WAWRZYNIAK  
STEVEN G. PARMELEE  
SHERRI N. BLOUNT\*  
BRUCE R. MANSFIELD  
KENDREW H. COLTON\*  
G. PAUL EDGELL\*  
RICHARD W. SCHUMACHER  
MICHAEL A. SANZO\*

CHRISTOPHER E. GEORGE\*  
SCOTT J. MENGHINI  
EDWARD E. CLAIR  
SANDRA V. SCAVO  
JON A. BIRMINGHAM  
RUDY KRATZ  
RAMON R. HOCH\*  
JOHN E. LYHUS  
STEVEN M. FREELAND  
DONNA E. BECKER  
SEAN R. O'DOWD  
MICHAEL G. VRANICAR  
BRIAN S. CLISE  
MARTIN R. BADER  
DEREK L. PRESTIN  
MARK A. BORSOS  
DAVID R. JAGLOWSKI  
W. BRIAN EDGE\*

PATENT AGENTS

ERIC J. WHITESELL  
JONATHAN H. BACKENSTOSE  
LILIA I. SAFONOV

OF COUNSEL

THOMAS F. LEBENS  
GEORGE W. SPELLMIRE, JR.  
LISA M. SOMMER

December 9, 2003

Commissioner of Patents  
U.S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window, **MS Patent Application**  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

Re: Continuation Patent Application  
(Continuation of U.S. 10/222,990)  
Appl. No.: to be assigned  
Filed: herewith  
For: **Novel Compounds with Analgesic Effect**  
Inventor(s): Delorme, *et al.*  
Atty. Dkt.: 7567/80916

Sir:

The following documents are being forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

1. A copy of application no. 10/222,990, as filed in the U.S. Patent and Trademark Office on August 19, 2002, comprising:

a title page naming Edward Roberts, Zhong Yong Wei  
and Daniel Delorme as inventors (unnumbered)  
102 pages of specification (numbered as pages 1-102)  
22 pages of claims (numbered as pages 103-124) and  
a one page abstract (numbered as page 125);

\*ADMITTED TO D.C. BAR; D.C. PRACTICE OF  
ALL OTHERS LIMITED TO FEDERAL COURTS  
AND AGENCIES



Commissioner of Patents

December 9, 2003

Page 2

2. A copy of the Declaration (37 C.F.R. § 1.63) and Power of Attorney executed by the inventors and filed in the great-grandparent application (09/029,633) (4 pages);
3. Preliminary Amendment (3 pages);
4. A copy of the recorded Assignment to Astra Pharma Inc. executed by the inventors and filed in the great-grandparent application (09/029,633) (5 pages);
5. A copy of the Merger document assigning rights from Astra Pharma Inc. to AstraZeneca Canada Inc. filed in the great-grandparent application (09/029,633) (8 pages);
6. General Authorization for Petition for Extension of Time Under 37 C.F.R. § 1.136(a)(3) (1 page);
7. General Authorization to Charge Deposit Account (1 page);
8. Information Disclosure Statement (2 pages);
9. List of References Cited by Applicant (2 pages); and
10. Two (2) return postcards.

This application is a continuation of U.S. application no. 10/222,990, filed on August 19, 2002, which is a continuation of U.S. application no. 09/761,833, filed on January 18, 2001 (now U.S. 6,455,545). The '833 application is a continuation of U.S. application no. 09/029,633, filed on March 5, 1998 (now U.S. 6,187,792). The '633 application represents U.S. national stage of international application PCT/SE97/02050, which had an international filing date of December 9, 1997, and which claims priority to Swedish application nos. 9604785-7, filed on December 20, 1996 and 9702535-7, filed on July 1, 1997.

The entire disclosure of the prior application, from which an oath or declaration is being supplied herewith in copy form, is considered a part of the disclosure of the accompanying continuation application and is hereby incorporated by reference.

In accordance with the requirements of 37 C.F.R. § 1.53(b), the present continuation application is being filed under the conditions specified in 35 U.S.C. § 120. The inventors named on this continuation application are the same as the inventors named on the parent, and the

Commissioner of Patents

December 9, 2003

Page 3

application is being filed before the patenting, or abandonment of, or termination of proceedings of the parent application (10/222,990). The application is being filed without the filing fee.

We are submitting an Information Disclosure Statement which cites references originally submitted in connection with the parent application, U.S. 09/222,990. The present application relies upon 09/222,990 for priority under 35 U.S.C. § 120. Thus, in accordance with 37 C.F.R. § 1.98(d), copies of the listed references are not being submitted. If, for any reason, the Examiner cannot locate a listed reference, Applicants will be happy to submit a copy as a courtesy.

A separate written request under 37 C.F.R. §1.136(a)(3), which is a general authorization to treat any concurrent or future reply requiring a petition for an extension of time under 37 C.F.R. §1.136(a) for its timely submission as incorporating a petition for an extension of time for the appropriate length of time, is enclosed.

A separate written request, which is a general authorization to charge any additional fees which may be required in this application under 37 C.F.R. §§1.16-1.17 during its entire pendency, or credit any overpayment, is enclosed.

#### **Fee Calculation**

Applicants calculate the filing fee is as follows:

	<b>Total</b>		<b>No. Extra</b>	<b>Rate</b>	<b>Fee</b>
<b>Basic Filing Fee</b>					<b>770.00</b>
<b>Total Claims Fee</b>	<b>30</b>	<b>20=</b>	<b>10</b>	<b>\$ 18.00</b>	<b>180.00</b>
<b>Independent Claims Fee</b>	<b>2</b>	<b>3 =</b>	<b>0</b>	<b>\$ 86.00</b>	<b>0.00</b>
<b>Multiple Dependent Claims Fee</b>				<b>\$ 290.00</b>	<b>290.00</b>
<b>TOTAL FEES DUE</b>					<b>\$ 1,240.00</b>

**This application is being filed without the filing fee.**

Commissioner of Patents  
December 9, 2003  
Page 4

**Correspondence in this case should be directed to:**

**Michael A. Sanzo  
Fitch, Even, Tabin & Flannery  
1801 K Street, N.W., Suite 401L  
Washington, DC 20006-1201  
Phone: (202) 419-7013  
Fax: (202) 419-7007**

It is respectfully requested that the enclosed postpaid postcards be stamped with the serial number and the date the enclosed documents are received by the PTO and that they be returned as soon as possible.

Respectfully requested,

FITCH, EVEN, TABIN & FLANNERY

A handwritten signature in black ink that reads "Michael A. Sanzo". The signature is written in a cursive, flowing style.

Michael A. Sanzo  
Attorney for Applicants  
Registration No. 36,912

MAS:ct  
Attachments

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re patent application of:

Delorme, *et al.*

(Cont. of Appl. No.: 10/222,990)

Filed: herewith

Appl. No.: to be assigned

For: **Novel Compounds with Analgesic Effect**

Art Unit: to be assigned  
(1625 in parent case)

Examiner: to be assigned  
(E. Huang in parent case)

Atty. Dkt.: 7567/80916

**General Authorization for Petition for  
Extension of Time Under 37 C.F.R. § 1.136(a)(3)**

Commissioner of Patents  
U.S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window, **MS Patent Application**  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

Sir:


Applicants hereby request under 37 C.F.R. § 1.136(a)(3) by this general authorization that any concurrent or future reply submitted by Applicants to the United States Patent and Trademark Office for the above-identified patent application requiring a petition for an extension of time under § 1.136(a) for its timely submission be treated as incorporating therein a petition for an extension of time for the appropriate length of time.

If Applicants do not timely pay for any extension fee(s) pursuant to 37 C.F.R. § 1.136(a) which may become due for this application under 37 C.F.R. § 1.17 by check, the Director is hereby authorized to charge such fee(s), and any additional fees which may be required in this application under 37 C.F.R. §§ 1.16-1.17 during its entire pendency, or credit any overpayment, to Deposit Account No. 06-1135 under Order No. 7567/80916.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By



Michael A. Sanzo  
Reg. No. 36,912  
Attorney for Applicants

Date December 9, 2003  
1801 K Street, N.W., Suite 401L  
Washington, DC 20006-1201  
Phone: (202) 419-7013

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re patent application of:

Delorme, *et al.*

(Cont. of Appl. No.: 10/222,990)

Filed: herewith

Appl. No.: to be assigned

For: **Novel Compounds with Analgesic Effect**

Art Unit: to be assigned  
(1625 in parent case)

Examiner: to be assigned  
(E. Huang in parent case)

Atty. Dkt.: 7567/80916

**General Authorization to Charge Deposit Account**

Commissioner of Patents  
U.S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window, **MS Patent Application**  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

Sir:

The Commissioner is hereby authorized to charge any additional fees which may be required in this application under 37 C.F.R. §§1.16-1.17 during its entire pendency, or credit any overpayment, to Deposit Account No. 06-1135 under Order No. 7567/80916.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By



Michael A. Sanzo  
Reg. No. 36,912  
Attorney for Applicants

Date December 9, 2003  
1801 K Street, N.W., Suite 401L  
Washington, DC 20006-1201  
Phone: (202) 419-7013